Severe phosphoribosylpyrophosphate synthetase superactivity Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

No FDA or trial events recorded yet for Severe phosphoribosylpyrophosphate synthetase superactivity.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Aurlumyn

BTG International Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Aurlumyn

(iloprost)Orphan drugstandard

BTG International Inc.

Prostacycline [EPC]

12.1 Mechanism of Action Iloprost is a synthetic analog of prostacyclin PGI 2 . Iloprost is a vasodilator and inhibits platelet aggregation.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Severe phosphoribosylpyrophosphate synthetase superactivity.
Search all trials →

Search clinical trials for Severe phosphoribosylpyrophosphate synthetase superactivity →

Recent News & Research

No recent news articles indexed yet for Severe phosphoribosylpyrophosphate synthetase superactivity.
Search PubMed for Severe phosphoribosylpyrophosphate synthetase superactivity →

Browse all Severe phosphoribosylpyrophosphate synthetase superactivity news →

Specialist Network

No specialists currently listed for Severe phosphoribosylpyrophosphate synthetase superactivity.

View all Severe phosphoribosylpyrophosphate synthetase superactivity specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰